序号 |
标题 |
次数 |
作者 |
发布时间 |
86041 |
3,6-二取代苯基-1,4-二氢-S-四嗪-1,4-二甲酸甲酯化合物 |
106 |
WYQ |
2024-11-28 |
86042 |
3-氧代-5-取代芳基异唑[3,4-e]并-1,2,3,4-四嗪衍生物 |
104 |
WYQ |
2024-11-28 |
86043 |
cas:619300-53-7 DOTA-NOC;DOTA-Nal3-octreotide |
105 |
zcy |
2024-11-28 |
86044 |
CAS:157599-02-5 1,4,7,10-四(氨基羰甲基)-1,4,7,10-四氮杂环十二烷 |
98 |
zyl |
2024-11-28 |
86045 |
DOTA-peptide-(GGGF)-m170的结构组成 |
172 |
wyh |
2024-11-28 |
86046 |
DOTA-3P-RGD ,双功能螯合剂DOTA偶联环肽RGD二聚体 |
222 |
kx |
2024-11-28 |
86047 |
CAS:913542-71-9 DOTA di(tBu)ester |
102 |
zyl |
2024-11-28 |
86048 |
cas: 1192362-32-5 DOTA-LM3 |
133 |
zcy |
2024-11-28 |
86049 |
DOPE-PEG-DOTA 磷脂-聚乙二醇-大环配体 |
94 |
zyl |
2024-11-28 |
86050 |
DOTA-GX1 , 大环螯合剂DOTA缀合GX1肽 |
109 |
kx |
2024-11-28 |
86051 |
甲氧基DOTA;MeO-DOTA |
307 |
wyh |
2024-11-28 |
86052 |
cas:865470-67-3 DOTA-Thiol |
132 |
zcy |
2024-11-28 |
86053 |
3-芳基-6-甲基-1,6-二氢-1,2,4,5-四嗪-1-烷基酮 |
122 |
WYQ |
2024-11-28 |
86054 |
DOTA-tris(acid)-amido-dPEG-TFP ester |
113 |
zyl |
2024-11-28 |
86055 |
DOTA-赖氨酸(DOTA-L) |
150 |
kx |
2024-11-28 |
86056 |
p-NH2-benzyl-NOTA; p-NH2-苄基-NOTA缀合物 |
102 |
wyh |
2024-11-28 |
86057 |
3-芳基-6-甲基-1,6-二氢-1,2,4,5-四嗪-1-甲酸酯 |
87 |
WYQ |
2024-11-28 |
86058 |
cas:1908409-18-6 DOTA Zoledronate DOTA唑来膦酸盐 |
122 |
zcy |
2024-11-28 |
86059 |
CAS:177943-88-3 DOTATATE |
123 |
zyl |
2024-11-28 |
86060 |
钆-四氮杂环十二烷-四乙酸 , LPS+Gd-DOTA |
136 |
kx |
2024-11-28 |
86061 |
N-取代苯基-3-芳基-6-甲基-1,6-二氢-1,2,4,5-四嗪-1-甲酰胺 |
191 |
WYQ |
2024-11-28 |
86062 |
DOTA-RM2;胃泌素释放肽受体的示踪剂 |
146 |
wyh |
2024-11-28 |
86063 |
DOTA-(t-butyl)3-PEG5-azide(大环化合物) |
129 |
zcy |
2024-11-28 |
86064 |
Tm-Maleimido-DOTA cas1552305-24-4 双功能螯合剂 |
107 |
zyl |
2024-11-28 |
86065 |
DOTA-tris(OPp酯)缀合物 , DOTA-tris(tBuester) |
123 |
kx |
2024-11-28 |
86066 |
4-乙氧羰基-1,7-二氢-1-取代苯基-5-(未)取代吡唑啉[5,1-d][1,2,3,5]四嗪-7-酮衍生物 |
99 |
WYQ |
2024-11-28 |
86067 |
1-取代-3-芳基-6-甲基-1,6-二氢-1,2,4,5-四嗪中N1位亚甲基(CH2) |
123 |
WYQ |
2024-11-28 |
86068 |
DOTA-AMBF3-PEG2-LLP2A;DOTA偶联跨膜蛋白极晚期抗原4 (VLA-4)的肽LLP2A |
188 |
wyh |
2024-11-28 |
86069 |
1-烷基-3-苯基-6-甲基-1,6-二氢-1,2,4,5-四嗪构象研究 |
121 |
WYQ |
2024-11-28 |
86070 |
DOTA-MUT-DS ,环状2-螺旋小蛋白偶联大环DOTA |
159 |
kx |
2024-11-28 |
86071 |
cas:2353410-19-0 Bromoacetamido-PEG5-DOTA 溴乙酰氨基-五聚乙二醇-DOTA |
164 |
zcy |
2024-11-28 |
86072 |
DOTA单酰胺螯合物偶联CLT1肽 , CLT1-dL-(Gd-DOTA) |
116 |
kx |
2024-11-28 |
86073 |
3-芳基-6-甲基-1,6-二氢-1,2,4,5-四嗪-1-烷基酮 |
92 |
WYQ |
2024-11-28 |
86074 |
3-芳基-6-甲基-1,6-二氢-1,2,4,5-四嗪-1-甲酸酯 |
104 |
WYQ |
2024-11-28 |
86075 |
DOTA修饰的声敏脂质体(GdSL ) , DOTA-GdSL |
189 |
kx |
2024-11-28 |
86076 |
1189194-65-7,DOTA-CH2-Alkynyl (TFA salt) |
110 |
zcy |
2024-11-28 |
86077 |
N-取代苯基-3-芳基-6-甲基-1,6-二氢-1,2,4,5-四嗪-1-甲酰胺 |
112 |
WYQ |
2024-11-28 |
86078 |
1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸的酯化前体(DOTA18) |
109 |
kx |
2024-11-28 |
86079 |
1610950-41-8,DOTA-甲基四嗪 |
112 |
zcy |
2024-11-28 |
86080 |
204318-14-9,Edotreotide,奥曲肽的多肽,DOTA大环化合物 |
106 |
zcy |
2024-11-28 |
86081 |
DOTA缀合的9聚体高亲和力uPAR结合肽 , DOTA-AE105 |
130 |
kx |
2024-11-28 |
86082 |
环糊精金属有机框架/海藻酸钙复合材料 γ-CD-MOF-SH/CA |
129 |
h |
2024-11-28 |
86083 |
四氮杂环十二烷四乙酸-琥珀酰亚胺酯 |
136 |
zyl |
2024-11-28 |
86084 |
β环糊精改性聚甲基丙烯酸甲酯-机金属骨架ZIF8 βCD/ZIF8/PMMA |
101 |
h |
2024-11-28 |
86085 |
G5-(Gd-DOTA)(96) ,DOTA-钆(Gd)的大分子造影剂 |
189 |
kx |
2024-11-28 |